Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the stock.

Other equities research analysts have also issued reports about the stock. Lake Street Capital lowered their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, March 4th.

Ekso Bionics Stock Down 0.9 %

Shares of Ekso Bionics stock opened at $0.41 on Friday. Ekso Bionics has a twelve month low of $0.34 and a twelve month high of $1.53. The stock has a market cap of $11.85 million, a price-to-earnings ratio of -0.63 and a beta of 1.33. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average price of $0.45 and a 200 day moving average price of $0.64.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. Equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.